These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rush to protect lucrative antibody patents kicks into gear. Ledford H Nature; 2018 May; 557(7707):623-624. PubMed ID: 29844545 [No Abstract] [Full Text] [Related]
3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia. Ortega Martínez de Victoria E Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604 [No Abstract] [Full Text] [Related]
4. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia. Ascaso JF Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861 [No Abstract] [Full Text] [Related]
5. Engineering antibodies for clinical applications. Jain M; Kamal N; Batra SK Trends Biotechnol; 2007 Jul; 25(7):307-16. PubMed ID: 17512622 [TBL] [Abstract][Full Text] [Related]
6. Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014. Larrick JW; Parren P; Huston JS; Plückthun A; Bradbury A; Tomlinson IM; Chester KA; Burton DR; Adams GP; Weiner LM; Scott JK; Alfenito MR; Veldman T; Reichert JM MAbs; 2014; 6(5):1115-23. PubMed ID: 25517297 [TBL] [Abstract][Full Text] [Related]
7. [Modern Lipid therapy today and tomorrow: anti-PCSK9 : A magic bullet concept following Paul Ehrlich]. Erbel R; Gitt AK Herz; 2016 Jun; 41(4):271-2. PubMed ID: 27241696 [No Abstract] [Full Text] [Related]
8. Engineering at the limits of antibody space. Huston JS Protein Eng Des Sel; 2013 Oct; 26(10):559-60. PubMed ID: 24077692 [No Abstract] [Full Text] [Related]
9. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview. Noel ZR; Beavers CJ Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895 [TBL] [Abstract][Full Text] [Related]
10. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. Navarese EP; Kolodziejczak M; Kereiakes DJ; Tantry US; O'Connor C; Gurbel PA Ann Intern Med; 2016 May; 164(9):600-7. PubMed ID: 26999484 [TBL] [Abstract][Full Text] [Related]
11. Reduction of cardiovascular risk with evolocumab (Repatha). Med Lett Drugs Ther; 2017 Apr; 59(1519):63-64. PubMed ID: 28419071 [No Abstract] [Full Text] [Related]